Forgot your password?

Forgot your username?

Mast Therapeutics, Inc.

12390 El Camino Real, Suite 150
San Diego, CA 92130 United States
Click for website
Research Sector Pharmaceutical
Summary Description Hematology and oncology-focused biopharmaceutical company with three clinical-stage product candidates.

Click here for Financial Data Keywordssickle cell disease, microvascular, hematology, oncology, shock, copolymer, chemotherapy, nonsmallcelllungcancer, lungcancer, breastcancer, solidtumor, cytoprotective, ischemia, acutelimbischemia


Mast Therapeutics, Inc. (NYSE MKT: MSTX) is a publicly traded biopharmaceutical company headquartered in San Diego, California. The Company is leveraging the MAST (Molecular Adhesion and Sealant Tech......view more

Products / Services

Mast's lead product candidate, MST-188 (formerly ANX-188) is a purified form of a nonionic, triblock copolymer (poloxamer 188). It binds to hydrophobic surfaces on damaged cells and improves membrane ......view more

Technology / Differentiation

MST-188 is an investigational agent, formulated using a purified form of poloxamer 188. Substantial research has demonstrated that poloxamer 188 has cytoprotective and hemorrheologic properties and in...view more


- The company is currently recruiting patients with sickle cell disease to participate in EPIC, its phase 3 trial of MST-188. At the end of March, 2013, the European Commission designated MST-188 as a...view more